Considerations for treatment duration in responders to immune checkpoint inhibitors
Open accessThe DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index.
Abstract
Immune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, however, optimal duration of ICI therapy has yet to be defined. Given ICIs were first used to treat patients with metastatic melanoma, a condition that at the time was incurable, little attention was initially paid to how much therapy would be needed for a durable response. As the early immunotherapy trials have matured past 10 years, a significant per cent of patients have demonstrated durable responses; it is now time to determine whether patients have been overtreated, and if durable remissions can still be achieved with less therapy, limiting the physical and financial toxicity associated with years of treatment. Well-designed trials are needed to identify optimal duration of therapy, and to define biomarkers to predict who would benefit from shorter courses of immunotherapy. Here, we outline key questions related to health, financial and societal toxicities of over treating with ICI and present four unique clinical trials aimed at exposing criteria for early cessation of ICI. Taken together, there is a serious liability to overtreating patients with ICI and future work is warranted to determine when it is safe to stop ICI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“long-term PD-1 blockade predisposes patients to a higher risk of irAEs and increased financial burden without a proven effect on outcomes129.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Cited by
Items 101–143 of 143
Oya, M., Ito, T., Sato, M., Morita, M., Kajita, M., & Nonomura, N. (2025) · Cancer Medicine · doi:10.1002/cam4.70186 · Cited by 2
Soon, J. A., Franchini, F., Gourlay, P., IJzerman, M. J., & McArthur, G. A. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.116132 · Cited by 1
Gosmann, D., Russelli, L., Käsbauer, T., Bissenberger, S., Bassermann, F., Weber, W., D’Alessandria, C., & Krackhardt, A. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.23.693936 · Cited by 1
Plais, H., Dumont, C., Gauthier, H., & Culine, S. (2023) · Immunotherapy · doi:10.2217/imt-2022-0283 · Cited by 1
Fujii, K., Fukuda, K., Kawakami, M., Mitani, A., Tanaka, G., & Kage, H. (2023) · Case Reports in Oncology · doi:10.1159/000533705 · Cited by 1
Evaluating the Efficacy of Immunotherapy in Fragile Hospitalized Patients
Rajadurai, C. V., Gagnon, G., Allard, C., Malick, M., & Pavic, M. (2024) · Current Oncology · doi:10.3390/curroncol31110518 · Cited by 1
Kozlov, A., Komarova, Y., Potanin, A. A., Галимов, А. Н., Morozova, E. V., Gevorgyan, A. G., Bykova, T. A., Kazantsev, I. V., Mikhailova, N. B., Bogdanova, O., et al. (2023) · Cellular Therapy and Transplantation · doi:10.18620/ctt-1866-8836-2023-12-3-17-22 · Cited by 1
Ridder, K. D., Vinchesi, M. C., Giron, P., Sohrab, N., Cuppens, K., Korkmaz, E. T., Ulas, E. B., Bahce, I., Decoster, L., & Goyvaerts, C. (2025) · medRxiv · doi:10.1101/2025.11.10.25339842 · Cited by 1
Fung, T., & Samlowski, W. E. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1655448 · Cited by 1
Rota, S., Sciortino, C., Damian, S., Duca, M., Villa, G., Monte, M. D., Ebrahem, E., Cattaneo, L., Volpi, C. C., Casale, A., et al. (2025) · Cancer Reports · doi:10.1002/cnr2.70397 · Cited by 1
Safety of dermatologic surgery during immune checkpoint inhibitor therapy
Davis, M. J., Trager, M. H., Erfani, Y. J., Dusza, S. W., Markova, A., Lee, E., Nehal, K., & Connolly, K. L. (2026) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2026.03.007 · Cited by 1
Costa-Martins, S., Valente, M., Pêgo, A., Figueiredo, A. A., & Barata, F. J. (2022) · Revista do Grupo de Estudos do Cancro do Pulmão · doi:10.32932/gecp.2022.02.020 · Cited by 1
How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability
Khan, M. R., & Forde, P. M. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-03105 · Cited by 1
Engineered Nanomaterials Chemical Characteristics for Cancer Immunotherapy
Islam, M. A., Chowdhury, M. S., Hasan, M. J., Rayhan, M. T., Islam, S., Hossain, N., & Mobarak, M. H. (2024) · Nano LIFE · doi:10.1142/s1793984424300127
Wen, X., 李浥涵, Hu, Y., Chen, A., Wang, K., Zou, W., Xie, B., & Ma, Y. (2026) · Technology in Cancer Research & Treatment · doi:10.1177/15330338261465744
Impact de la radiothérapie interne vectorisée alpha sur le microenvironnement tumoral
Perrin, J. (2021) · theses.fr (ABES) · doi:10.70675/31c91866z101fz4e07zbde2z6887a8fdba6d
Wang, S., Liu, J., Nie, Q., Shi, R., Xu, N., He, Q., Ye, G., Liu, J., Hou, Q., 邓克学, et al. (2026) · MedComm · doi:10.1002/mco2.71032
Ferdinandus, J., Zaremba, A., Zimmer, L., Umutlu, L., Seifert, R., Barbato, F., Ugurel, S., Chorti, E., Grünwald, V., Herrmann, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19128719
Ferdinandus, J., Zaremba, A., Zimmer, L., Umutlu, L., Seifert, R., Barbato, F., Ugurel, S., Chorti, E., Grünwald, V., Herrmann, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19128716
Ferdinandus, J., Zaremba, A., Zimmer, L., Umutlu, L., Seifert, R., Barbato, F., Ugurel, S., Chorti, E., Grünwald, V., Herrmann, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19128713
Ferdinandus, J., Zaremba, A., Zimmer, L., Umutlu, L., Seifert, R., Barbato, F., Ugurel, S., Chorti, E., Grünwald, V., Herrmann, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19128725
Ferdinandus, J., Zaremba, A., Zimmer, L., Umutlu, L., Seifert, R., Barbato, F., Ugurel, S., Chorti, E., Grünwald, V., Herrmann, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19128728
Ferdinandus, J., Zaremba, A., Zimmer, L., Umutlu, L., Seifert, R., Barbato, F., Ugurel, S., Chorti, E., Grünwald, V., Herrmann, K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19128722
Cancer Immunotherapy Clinical Trials
Kwapisz, D. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_205-2
Cancer Immunotherapy Clinical Trials
Kwapisz, D. M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00767-4_205
Immunotherapy with Checkpoint Inhibitors
Vickers, E. (2024) · Wiley eBooks · doi:10.1002/9781119834090.ch5
Immunotherapy and Cancer: The Pharmacists’ Perspective
Gundrum, D. A., Piccolo, J. K., & Sahu, K. K. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_215-1
Immunotherapy and Cancer: The Pharmacists’ Perspective
Gundrum, D. A., Piccolo, J. K., & Sahu, K. K. (2025) · Springer eBooks · doi:10.1007/978-3-032-00767-4_215
Pragmatic solutions for optimizing oncology drug development trials
Verweij, J., Longson, C. M., von Lilienfeld‐Toal, M., Cahane, D., Evans, T. R. J., Chiou, V. L., Lacombe, D., Gravis, G., & Goldstein, D. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00054-x
Valeur pronostique et prédictive de l’Immunoscore dans les cancers du côlon et de la vessie
Pol, J. G. (2021) · HEGEL - HEpato-GastroEntérologie Libérale · doi:10.3917/heg.112.0113
Mo, J., Bohne, A., Nägeli, M., Gaudy‐Marqueste, C., Chen, C., Zaremba, A., Park, J., Ladwa, R., Marta, N. D., Matias, M., et al. (2026) · EJC Skin Cancer · doi:10.1016/j.ejcskn.2026.101157
Zhang, Q., Wang, X., Chen, Y., Feng, H., Fu, X., Ren, H., & Wu, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1947402
Stepping on the Gas or Hitting the Brakes: Response-Driven Therapy for Melanoma
Amouzegar, A., Shaw, R., Tsai, K. K., Olson, D., & Gibney, G. T. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-520562
Self-citationVerstockt, B., Dragoni, G., van Schaik, F. D. M., Nunes, P. B., Burisch, J. M., Carbonnel, F., Dekervel, J., Driessen, A. L. C., Ordás, Í., Powell, N., et al. (2026) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjag148
Lewis, R. I., Seuthe, K., Lennartz, S., Weber, J.-P., Kreuzberg, N., Klingel, K., & Bröckelmann, P. J. (2024) · doi:10.3389/fcvm.2024.1328378.s001
Treatment duration of immune checkpoint inhibitors and overall survival in U.S. veterans with Cancer
Hassan, S. Z., Tague, M., Klein, M. A., & Lund, B. C. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251357811
Karimi, A. M., Khosravi, A., & Masoudi, N. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.110171
Younis, R. H., Mehra, R., & Nikitakis, N. G. (2025) · Frontiers in Oral Health · doi:10.3389/froh.2025.1635675
Self-citationvan Dijk, B., Janssen, J. C., Mulder, E. E. A. P., de Joode, K., & van der Veldt, A. A. M. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115635
Toxicity and treatment discontinuation with adjuvant immune checkpoint blockade: a correspondence
Zhong, R. M., Huang, L., & Tang, P. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003466
Zulkifli, N. S., Tam, L., Mclean, A., & Atkinson, V. G. (2026) · Internal Medicine Journal · doi:10.1111/imj.70415
Xu, C., Wang, Y., Liu, X., Huang, X., Jin, F., Yang, K.-Y., GuangYuan, H., Zhu, X.-D., Wang, Y., Zhang, N., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104307
Metadata
- Authors
- Marron, T. U., Ryan, A. E., Reddy, S. M., Kaczanowska, S., Younis, R. H., Thakkar, D., Zhang, J., Bartkowiak, T., Howard, R., Anderson, K. G., Olson, D., Naqash, A. R., Patel, R. B., Sachdev, E., Rodriguez-Ruiz, M. E., Sheffer, M., Church, S., Fuhrman, C., Overacre-Delgoffe, A., Nguyen, R., Florou, V., Thaxton, J. E., Aggen, D. H., & Guerriero, J. L.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- National University of Ireland (IE)
- The University of Texas Southwestern Medical Center (US)
- National Institutes of Health (US)
- University of Maryland, Baltimore (US)
- Hummingbird Scientific (United States) (US)
- Johns Hopkins University (US)
- Vanderbilt University (US)
- Moffitt Cancer Center (US)
- University of Washington (US)
- University of Chicago (US)
- University of Pittsburgh (US)
- University of Southern California (US)
- Clinica Universidad de Navarra (ES)
- Dana-Farber Cancer Institute (US)
- Transitional Sciences, NanoString Technologies Inc, Seattle, Washington, USA
- Nanostring Technologies (United States) (US)
- National Cancer Institute (US)
- Huntsman Cancer Institute (US)
- Medical University of South Carolina (US)
- Memorial Sloan Kettering Cancer Center (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Guerriero, Jennifer L
- ORCID
- Marron, Thomas U
- Ryan, Aideen E
- Reddy, Sangeetha M
- Kaczanowska, Sabina
- Younis, Rania H
- Thakkar, Dipti
- Zhang, Jiajia
- Bartkowiak, Todd
- Howard, Rachel
- Anderson, Kristin G
- Olson, Daniel
- Naqash, Abdul Rafeh
- Patel, Ravi B
- Rodriguez-Ruiz, Maria E
- Sheffer, Michal
- Fuhrman, Christopher
- Overacre-Delgoffe, Abigail
- Nguyen, Rosa
- Florou, Vaia
- Thaxton, Jessica E
- Aggen, David H
- Guerriero, Jennifer L
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2021-03
- Volume
- 9
- Issue
- 3
- Pages
- e001901
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC7929825
- OpenAlex
- W3134221665
- Cited by
- 137
- References
- 49
- Citations by year
- 2026: 13 · 2025: 31 · 2024: 21 · 2023: 36 · 2022: 31 · 2021: 5
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Greater South Information System
- Funders
- SITC SPARKATHON
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- immune checkpoint inhibitors, treatment duration, durable response, overtreatment, financial toxicity, health-related quality of life, treatment response biomarkers, early clinical trials, metastatic melanoma, immunotherapy toxicity
- MeSH terms
- Immune Checkpoint Inhibitors, Clinical Trials as Topic, Drug Administration Schedule, Humans, Neoplasms, Risk Factors, Time Factors, Treatment Outcome, Risk Assessment, Evidence-Based Medicine, Patient Safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.